Tech Company Financing Transactions

Tau Therapeutics Funding Round

On 12/18/2012, Tau Therapeutics secured $3 million in funding from private investors.

Transaction Overview

Company Name
Announced On
12/18/2012
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds will support Tau's Phase 1b clinical trial currently being conducted with the National Cancer Institute's Adult Brain Tumor Consortium. Additionally, the proceeds will support development of new therapies and diagnostics in multiple indications.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
600 East Water St. E
Charlottesville, VA 22902
USA
Email Address
Overview
Tau Therapeutics is a biotechnology company built on a revolutionary discovery of a Cytostatic Checkpoint Therapy TM that stops the growth of cancer cells. As the proprietors of this disruptive mechanism of action, Tau is focused on the research, development, repositioning and commercialization of calcium T-channel therapy agents.
Profile
Tau Therapeutics LinkedIn Company Profile
Social Media
Tau Therapeutics Company Twitter Account
Company News
Tau Therapeutics News
Facebook
Tau Therapeutics on Facebook
YouTube
Tau Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Andrew Krouse
  Andrew Krouse LinkedIn Profile  Andrew Krouse Twitter Account  Andrew Krouse News  Andrew Krouse on Facebook
Chief Medical Officer
Bruce Silver
  Bruce Silver LinkedIn Profile  Bruce Silver Twitter Account  Bruce Silver News  Bruce Silver on Facebook
Founder
Lloyd Gray
  Lloyd Gray LinkedIn Profile  Lloyd Gray Twitter Account  Lloyd Gray News  Lloyd Gray on Facebook
Founder
Timothy Macdonald
  Timothy Macdonald LinkedIn Profile  Timothy Macdonald Twitter Account  Timothy Macdonald News  Timothy Macdonald on Facebook
VP - Bus. Development
John McCray
  John McCray LinkedIn Profile  John McCray Twitter Account  John McCray News  John McCray on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/18/2012: Appfluent Technology venture capital transaction
Next: 12/18/2012: Tarveda Therapeutics venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on tech company VC transactions. VC transactions on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary